PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Psychosocial Complexity Does Not Predict Withdrawal During Methadone-Buprenorphine Transfer

buprenorphinemethadoneopioid agonist therapyopioid use disordermethadone-buprenorphine transferprecipitated withdrawalCOWSSOWSprospective cohortlow-dose inductionstop-and-start Behavioral Health / Addiction Medicine

Background Information

Withdrawal during methadone-to-buprenorphine transfers peaks and is predictable.

Understanding withdrawal experiences during methadone-to-buprenorphine transfers (MBT) can improve the management and support for patients in opioid agonist therapy. Withdrawal peaked around Day 5 and was not influenced by psychosocial factors. Low-dose transfer delayed peak withdrawal by 2.3 days and increased the severity slightly compared to stop-and-start methods. These results suggest that clinicians should plan for expected withdrawal without selecting patients based on perceived psychosocial complexity during MBT. Withdrawal during MBT is predictable, allowing strategic planning for patient support.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Tremonti C, Mills L, Lintzeris N, Blogg J, Jamshidi N, Harjanto R, Blazey A, Montebello M, Ismay C, Page R, Buckley NA, Perananthan V, Haber PS

Citation: Tremonti C, Mills L, Lintzeris N, et al. Patient Experience of Withdrawal During Methadone-Buprenorphine Transfer: A Prospective Cohort Study. Drug and alcohol review. 2026;45(5):e70211. doi:10.1111/dar.70211

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.